Background Psoriasis is a disease of enormous socio-economic impact. Despite approval of numerous highly efficient
Introduction
Psoriasis is a chronic inflammatory systemic disease with typical cutaneous manifestations and is one of the most frequent dermatological diseases worldwide. About 2 per cent of the German general population is affected. 1 Enormous progress has been made in developing innovative therapies that treat psoriasis symptoms efficiently. However, this is contrasted by the fact that only a minor proportion of necessitous psoriasis patients actually receive these treatments. 2 While this unsatisfactory fact might be explained partially by economical risk or by the behaviour of treating physicians, recently the personality of psoriasis patients themselves has become the focus of research for compliance and adherence. [3] [4] [5] It is generally accepted that psoriasis is a complex disease and there are several comorbidities associated with it. The German National Health Care Goals include the aim of detecting comorbidities early on in psoriasis, such as psoriatic arthritis, arterial hypertension, obesity, diabetes mellitus, metabolic syndrome and depression. [6] [7] [8] [9] Nicotine and alcohol abuse have also been discussed as comorbidities of psoriasis, and studies have shown that increased alcohol and tobacco consumption can be found in patients with this skin condition. [10] [11] [12] [13] [14] [15] However, it remains unclear whether patients with psoriasis have a higher risk of alcohol and nicotine abuse or whether patients addicted to these substances have a higher risk of psoriasis. Mental illnesses such as depression have been considered in several studies regarding psoriasis comorbidities, 7 and although alcohol and nicotine addictions are found more commonly in psoriasis patients compared with the general population, 11 other addictions such as drug abuse, food addiction, and gambling have not yet been investigated with regard to psoriasis. Gambling in particular should be the focus of attention due to the globally expanding gambling opportunities including the rise of online casinos, online gaming and betting. 16 As addictions in patients with psoriasis have not yet been investigated in detail, the effects of addictions and substance abuse on patient adherence, psoriasis treatment and the performance of anti-psoriatic drugs remain unclear. The goal is also to define suitable recommendations for dermatologists to detect addictive risk behaviours early on and implement adequate interdisciplinary treatment approaches for psoriasis patients with addictions.
Objective
The aim of this project is to investigate the prevalence of addictions in psoriasis and to develop evidence-based recommendations for dermatologists in their daily clinical practice.
Methods
The study was approved by the Ethics Committee of the Medical Faculty of the Technical University of Munich. All patients were over 18 years of age, and written informed consent was obtained prior to study inclusion. Participants did not receive a stipend. Inclusion criteria were a psoriasis diagnosis established by an experienced dermatologist based on clinical signs and symptoms, laboratory and histological findings, and medical treatment at the Technical University of Munich Department of Dermatology as an inpatient or outpatient due to moderate-to-severe psoriasis within the interdisciplinary competence centre of inflammatory skin diseases. Patients with insufficient language skills to answer a German questionnaire were excluded from the study. Of 110 psoriasis patients treated and asked to participate by the study doctors, 102 agreed to participate (Response rate 92.7%). Disease severity was assessed using the PASI (Psoriasis Area and Severity Index) scoring system as well as the DLQI (Dermatology Life Quality Index). Patients were then asked to anonymously complete a paper-based questionnaire on addictive behaviour. They were also asked to complete a section concerning demographic information (sex, age). The questionnaire included a total of 92 custom-assembled items based exclusively on validated and internationally recognized addiction screening tools. Innumerable addictions have been known to afflict human beings; however, we restricted our analysis to the six most common addictions in Germany and many other countries: alcohol abuse, tobacco abuse, drugs, illegal drugs, gambling, eating disorders (especially food addiction, anorexia, etc.). Body weight and height were also documented on the questionnaire to calculate the body mass index (BMI).
Alcohol abuse
The CAGE questionnaire was used to screen for alcohol problems. The CAGE questionnaire is a well-established and extensively validated screening test consisting of four questions, which form its name 'CAGE' as an acronym 17 :
The CAGE questionnaire has been extensively validated for use in identifying alcoholism. 1 Have you ever felt you needed to Cut down on your drinking? 2 Have people Annoyed you by criticizing your drinking? 3 Have you ever felt Guilty about drinking? 4 Have you ever felt you needed a drink first thing in the morning (Eye-opener) to steady your nerves or to get rid of a hangover? Two answers marked with 'Yes' indicate the possibility of alcoholism and a need of further investigation. Studies have shown CAGE questionnaire answers ≥2 have a specificity of 76% and a sensitivity of 93% for the identification of problematic drinking. 18 
Tobacco
Questions on tobacco consumption included the frequency of smoking (never, social smoker and regular smoker) as well as the number of cigarettes smoked each day (less than 1 pack per day, 1 pack per day, 1.5 packs per day, 2 packs per day, more than 2 packs per day) and years of smoking.
Drugs and illegal drugs
To provide a quick index of drug abuse problems, the Drug Abuse Screening Test (DAST-10) was used. DAST-10 was developed as a self-report instrument for screening and making treatment evaluations. The test consists of 10 questions that refer to drug use in the past 12 months and are answered with 'Yes' or 'No'. For each question answered with 'Yes', 1 point is scored except one question that is reverse-scored. Depending on the score, the Degree of Problems Related to Drug Abuse is graded as 'No problems reported' (Score 0), 'Low level' (Scores 1-2), 'Moderate level' (Scores 3-5), 'Substantial level' (Scores 6-8) and 'Severe level' (Scores 9-10). 19 Addiction Scale (YFAS). The YFAS was the first tool specifically designed for the assessment of signs for addictive-like eating behaviour assessed via 25 items. Although there is not yet an official diagnosis of 'food addiction', the YFAS aims to identify persons with symptoms of dependency towards food, regardless of weight. The shortened mYFAS was developed for screening in large epidemiologic cohorts by shortening the validated YFAS down to 9 questionnaire items; the short version was validated in 2014. 21 People with answers meeting the threshold for food addiction according to the mYFAS definition were categorized as 'food addictive' and those that met the threshold only partially were classified as at 'risk of food addiction'.
Gambling
Gambling addiction was assessed using the 'Gamblers Anonymous Twenty Questions' (GA-20). 22 The screening test GA-20
was developed by Gamblers Anonymous, a worldwide organization founded in 1957 for men and women with gambling problems who desire to stop gambling. The GA-20 is based on the difficulties and problems experienced by members of Gamblers Anonymous and it is a measure that allows self-assessment of gambling problems. Answering seven or more questions with 'Yes' implies compulsive gambling.
Statistics
Data from the study population were compared to the general population data in Germany, which is published annually by the German Federal Ministry of Health 23 and the 'German Health
Interview and Examination Survey for Adults (DEGS1)'. 24, 25 Chi-square tests and t-tests were used, respectively, and a statistical significance of P < 0.05 was used throughout. SAS (version 9.2; SAS Institute Inc., Cary, NC, USA) was used for all statistical tests.
Results
One hundred and two patients (65 males, 37 females) with psoriasis answered the study questionnaire on addictions between October 2015 and February 2016. Their average age was 49.7 years (SD 13.4) and all patients were on systemic treatment due to a moderate-to-severe psoriasis which included methotrexate, cyclosporine, fumaric acids, apremilast and biologics. Of the calculated BMI of the 102 subjects, only 29.4% (n = 30) have a BMI classified as 'normal weight' by the World Health Organization (WHO), which falls between 18.5 and 24.99, whereas 28.4% (n = 29) are 'overweight' (BMI 25-29.99), 25.5% (n = 26) are 'moderately obese' (BMI 30-34.99), 12.8% (n = 13) are 'severely obese' (BMI 35-39.99) and 3.9% (n = 4) are 'very severely obese' (BMI >40) ( Table 1) . A correlation between the PASI at the study visit and BMI was not seen. The mean BMI of all patients was 29.5 (SD 6.4) with a range from 18.4 to 58.1. BMI results are significantly higher when comparing the study population with the general population (P < 0.001), as well as when comparing the female study population with the general female population (P < 0.005) and the male study population with the general male population (P < 0.005).
Alcohol
Seventy-eight patients (77.3%) reported drinking alcohol and one patient did not answer the questions on drinking. These 78 patients were divided into groups: low-risk alcohol consumption with a maximum of drinking four times per month (54 patients, 76.2%), and high-risk alcohol consumption, that is drinking three or more times a week (24 patients, 23.8%). Alcohol consumption was significantly higher compared with the general population (P < 0.005). In 13 patients (13.5%), alcohol dependence was classified as 'probable' according to the evaluation of the answers given on the CAGE questionnaire with two or more 'Yes' answers. Seven patients answered two CAGE question with a 'Yes', 5 patients answered three questions with 'Yes' and 1 patient chose 'Yes' for all four questions. Eight patients answered only one question with 'Yes' and were therefore not classified as 'at risk' according to the CAGE questionnaire guidelines (for sex distribution, see Table 2 ). Overall, alcohol dependency was significantly associated with disease severity measured via the PASI (Pearson's correlation coefficient of 0.29). Psoriasis and addictions in the study population is significantly higher compared with the general population in Germany (P < 0.001) ( Tables 1  and 2 ).
Drugs and illegal drugs
Ten per cent of 100 patients with psoriasis who answered the questions for drugs and illegal drugs were assessed as 'being at risk' of drug addiction (DAST-10 Score of 3-5) and 1 individual (1%) was classified as drug addictive according to the scoring system (DAST-10, Score of 9). No gender differences were found. A significant association with disease severity (PASI) was seen (Pearson's correlation coefficient 0.26).
Food addiction and BMI
Ninety-seven participants answered the questions for food addictions and in all patients' body weight and height were documented and the BMI was calculated. Three patients (3.1%) were classified with dependency and one other patient (1.0%) with a risk of dependency for food according to their answers on the mYFAS. All three patients with food dependency were 'very obese' with a BMI above 35 (exact BMIs were 37.9, 40 and 43.4), whereas the one patient with a 'risk of dependency' had a BMI of 25.3. In all other patients, including the 'severely obese' and 'very severely obese' (15.9%, n = 17), no food addictions were detected using the mYFAS as a screening tool.
Disease severity and addiction
Disease severity, evaluated on the single study visit by the PASI, was significantly associated with alcohol addiction measured by the CAGE questionnaire and the risk of drug abuse. The other addictions were not associated with disease severity on the day of the study.
Gambling
The GA-20 questions on gambling were answered by 100 psoriasis patients. Nineteen patients (19.0%) were classified as compulsive gamblers. Compared with the general population, gambling in psoriasis patients was significantly higher (P < 0.001). No gender differences were found ( Table 2) .
Discussion
This proof-of-concept study is the first to investigate the risk of addiction in detail and its possible consequences for psoriasis patients. We demonstrate a significantly higher prevalence of addictions, especially gambling, in patients with psoriasis.
Results for alcohol and tobacco consumption are consistent with previous findings that have shown increased drinking and smoking habits in psoriasis patients. [26] [27] [28] However, there are no studies available for comparing our study findings regarding the significant increase in compulsive gambling, risky drug and illegal drug consumption, as well as food addictions in psoriasis patients compared with the general population. The significantly increased alcohol consumption found in the study population confirms the findings of previous studies that excessive drinking habits are more common in psoriasis patients. 11, 15 A smoking prevalence of 49% in the study population also supports previous publications that psoriasis patients are more likely to smoke compared with the general population. 15 The distribution of BMI in all study patients also reflects the BMI distribution of previous studies, such as the results of the PSOLAR study. 29, 30 Thus, our cohort seems to be representative of other psoriasis populations and can be compared to other psoriasis care centres.
Compared with the 19% of the study population with problematic gambling, the German Center for Addiction Issues indicates that the proportion of the general population with problematic gambling behaviour is only 1%. 31 At the same time, one must take into account that the questions of the GA-20 used in this study are very accurate in terms of pathological gambling in casinos and gambling halls, whereas today's widespread online gambling at home as well as video and Internet gaming might not fully be recognized. The age distribution of our sample could mean that several patients were in the typical age group that plays online computer gambling games. This might have contributed to an overestimation in our sample. Currently there are no available studies focusing on gaming and gambling in psoriasis patients. However, gaming and gambling, as well as the problematic behaviours that are associated with these, seem to be present in psoriasis patients, especially when compared to the general population, and thus, these aspects need further investigation.
Although there is an intense discussion regarding the possible explanations for the observations of higher BMI values, with the main theory currently focusing on psoriasis as a systemic inflammatory disease provoking -amongst others -metabolic syndrome in affected patients, simple lifestyle habits, and eating disorders might also have an effect. These aspects were addressed with the mYFAS questionnaire that showed respective risks in four patients. However, the mYFAS cannot differentiate between food addiction and other specific eating disorders such as binge eating.
Our study had a few limitations. The questionnaire, with its 92 items, was time-consuming and might have led to reduced patient attention during completion; information bias due to wrong answers cannot therefore be excluded completely. Further, the research was carried out as a monocentre study at a German university hospital dermatology department. Naturally, patients severely affected by psoriasis or with disease-specific complications are treated in university hospitals, whereas mild cases are usually seen by practice-based dermatologists. The study results therefore cannot be easily transferred to the general population suffering from psoriasis as patients with moderateto-severe psoriasis might have a different risk of addictions than patients with milder forms. Data in the study were collected only in psoriasis cases and then compared to the general population in 2011 24, 25 from other sources not corresponding to the same standards and in some cases using different addiction screening tools. However, only well-established and validated screening tools were used in the study allowing comparisons and statistical analysis. Further limitations include the following: we did not distinguish between first visits and follow-up visits of our psoriasis patients and also type or duration of treatment was not taken into account. PASI assessment on the single study day therefore might reflect a composite measure of the disease severity and adequacy of control at study inclusion. Possible explanations for the observed higher prevalence of addictive behaviour in patients with psoriasis compared with the general population are numerous. One could be the previously reported high risk of depression and anxiety 32 in patients with psoriasis, whereas other potential reasons range from the published association of 'psoriasis with a variety of psychological problems, including poor self-esteem, sexual dysfunction and suicidal ideation' 33 to 'lower social problem-solving skills' 34 and perceived stigmatization. 35 Although further investigations are hereby necessary, screening for addictions in psoriasis patients already is highly recommendable for today's daily practice. As the screening questionnaires used in our study are probably too time-consuming for dermatologists to use in daily practice, we propose four simple and quick questions as a prescreening (Table 3) . Questions answered with a 'Yes' could then be further evaluated with respective screening questionnaires followed by discussing the referral to an addiction specialist with the patient, if addictive behaviour is obvious. Naturally, interdisciplinary collaborations between dermatologists and addiction specialists have to be promoted for affected patients and this issue should be included in future psoriasis guidelines. Currently, available clinical scores to evaluate disease severity in psoriasis (e.g. PASI) only give a snapshot of disease severity on a particular day. Furthermore, previous PASI scores within the last few years are not taken into consideration and pretreatment is not considered. But comorbidities of psoriasis and especially addictions in general are not developed within a few days, for example, during a flare-up of psoriasis. They rather are developed within months or even years. That is why the individually highest documented disease severity might be crucial. This seems to be confirmed by our study results, whereby addictions are significantly more prevalent compared with the general population with significant associations of snapshot disease severity (PASI) on study day and under treatment only with alcohol dependency and compulsory gambling. It is also net yet understood, if and to what extent psoriasis treatment and especially the recently developed highly effective anti-psoriatic drugs reaching PASI90 or even PASI100 in the majority of patients 36 lower the risk of developing comorbidities. In HIV medicine, for example, it has been shown that the CD4 nadir (i.e. the lowest CD4 cell count ever in one HIV positive individual) is an impressive predictor of numerous comorbidities such as neurocognitive impairment independent of highly effective antiretroviral therapy. By analogy, we propose the 'PeakPASI' to document the individual lifetime impact of psoriasis disease severity: like the nadir CD4 + T-cell count in chronic HIV infection documents a person's lowest CD4 count, the PeakPASI documents an individual's highest PASI. In this manner, the PeakPASI could be a stable long-term grade to address the individual overall disease severity, independent of single-day PASI scores during differently effective treatment. For example, some patients' lifelong psoriasis only affects their elbows and knees with a PASI of <5, whereas others suffer from generalized forms with a PASI >10. During treatment, both patients might reach the same low PASI of <1, which obviously is not the ideal tool to assess long-term comorbidities. PeakPASI could help to differentiate between individual disease severity independently of current treatments, which seems essential in evaluating the risk of developing comorbidities in psoriasis. Addictive behaviour, if eventually confirmed as comorbidity of psoriasis, might be related to 'Cumulative Life Course Impairment' and thus be associated with several factors such as age of onset, refractoriness to treatment, stigmatization, family support or critical life events. The maximal degree of activity at any point in time might be one of these factors and might be well documented by PeakPASI. Naturally, the PeakPASI has to be evaluated in futures studies.
Conclusion
Addictions, especially gambling, seem to be substantially more common in patients with psoriasis compared with the general population. This should be taken into account by every dermatologist in terms of addressing possible addictions on a regular basis as well as choosing the individually 'best' anti-psoriatic drug. Further studies are needed to investigate addictive behaviour in a large number of patients with mild, moderate and severe psoriasis as well as its influence on the medical psoriasis treatment. Studies addressing these unmet needs in psoriasis patients and examining interdisciplinary solution strategies, including perhaps online approaches addressing gambling with Addiction Medical Specialists, will not only contribute to lowering the psoriasis burden of disease and its health economic costs, but will more importantly improve the treatment of psoriasis patients who have individual needs. Eventually, the interdisciplinary medical approach along with public health strategies, rather than the mere focus on insights into the pathogenesis of psoriasis, along with new drug developments may help to fulfil the unmet 21st century goal of a 'sustained psoriasis treatment' as requested by our patients and the WHO in their recent psoriasis resolution.
